Tiziana Life Sciences (NASDAQ: $TLSA) is a biotech firm, which is working on comprehensive research efforts to advance novel treatments, and improve patient outcome with neuroinflammatory disorders that include ALS, Alzheimer’s Disease, and na-SPMS.
On Tuesday, 18 February 2025, Tiziana announced the dosing of more patients in its Intermediate Size Patient Population Expanded Access (ISPPEA). Let us take a deep dive into this recent development.
Tiziana Announces The Dosing Of Additional Patients
Tiziana revealed that the expanded program would cover patients with non-active secondary progressive multiple sclerosis (na-SPMS) who did not meet the requirements of the current phase 2a study. To date, 14 patients have joined the program, with the first 10 showing improvements or stabilization within 6 months.
The new patients will receive access to intranasal foralumab, an investigational therapy developed by Tiziana. It aims to provide potential benefits to those who may not have access to this promising investigational therapy.
Commenting on the announcement, Tiziana CEO Ivor Elrifi stated that they were “pleased to reach this milestone.” He added that they remained dedicated to advancing their therapies and “look forward to further evaluating their potential through both expanded access and clinical trials.”
What Is Tiziana’s Foralumab?
Foralumab is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. There are currently 10 patients with na-SPMS that have been dosed with the therapy, with signs of improvement or stability within 6 months. Recently, Tiziana has received FDA approval to add 20 more patients in the expanded access program.
Currently, Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) that has reached the clinical development stage. The intranasal administration of the investigational therapy presents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.
Tiziana (TLSA) Stock Performance
Tiziana (TLSA) stock is up 16.47% as of Friday’s closing price of 0.7920. During the Friday, February 14, 2025, closing session, the stock gained 7.03%. Year to date, it is up 13.14%, while in the past 12 months, it is up 46.67%, beating the S&P 500, which is up 22.28% in the past year. Its Friday closing price is above its 50-day moving average of $0.7888 and below its 200-day moving average of $0.8997.
Analysts remain optimistic about the stock’s future, with analysts from Fintel forecasting a 289.36% upside for the stock by July 2025 at $3.06 per share. The analysts forecast the stock to be in the range of a low of $3.03 and a high of $3.15.
Should You Add Tiziana (TLSA) To Your Portfolio?
TLSA stock has outperformed the S&P 500 in the past 12 months, and they have recently announced FDA approval for an expanded access program in the treatment of neuroinflammatory disorders. A recent report by Fortune Business Insights estimates that the multiple sclerosis drugs market could be worth $38 Billion By 2032.
While the market is currently dominated by major players like Eli Lilly (NYSE: LLY), Biogen (NASDAQ: BIIB), and TG Therapeutics (NASDAQ: TGTX), Tiziana (TLSA) presents a unique market opportunity. Unlike other matured stocks, TLSA has the potential for explosive growth as clinical trials, which show a lot of promise, advance. Consequently, TLSA could potentially be a great addition to your portfolio for long-term growth.
Click Here For Updates on TLSA – It’s FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. We have been compensated ten thousand dollars electronically via bank wire by One Eyed Jack Enterprises LLC for an advertising / marketing campaign for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA) beginning on 2/13/2025 and ending on 2/20/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA).